Pharma-clinics le medicament du mois. Le rabeprazole (Pariet)

[en] Proton pomp inhibitors (PPI) have revolutionized the treatment of gastro-oesophageal reflux disease and gastro-duodenal ulcers. Rabeprazole (Pariet) is the last PPI arrived on the Belgian market. Controlled studies have shown an efficacy similar to emeprazole in the treatment of oeso-gastro-duodenal acid diseases. Rabeprazole has a favourable profile with rapid action and good safety.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Language :

French

Title :

Pharma-clinics le medicament du mois. Le rabeprazole (Pariet)

Alternative titles :

[en] Pharma-Clinics Medication of the Month. Rabeprazole (Pariet)

Publication date :

January 2002

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

53-6

Peer reviewed :

Peer reviewed

Available on ORBi :

since 05 October 2009

Statistics

Number of views

314 (2 by ULiège)

Number of downloads

244 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Louis E., Delooze D., Deprez P. (2002) Heartburn in Belgium: Prevalence, impact on daily life, and utilization of medical resources. Eur J Gastroenterol, in press; .
Louis E., Belaiche J. (2000) Reflux gastro-oesophagien de l'adulte: Diagnostic et traitement. Rev Med Liège 55:341-344.
Van Kemseke C., Belaiche J. (2000) Recommandations dans la prise en charge de l'Helicobacter pylori: Point de vue récent de la Société Nationale Française de Gastroentérologie. Rev Med Liège 55:345-349.
Sachs G., Modlin M.I. Acid related disease: biology and treatment, Schnetzer-Verlag, ISBN 3-87018-144-3; 1998.
Besancon M., Simon A., Sachs G., Shin J.M. (1997) Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 272:22438-22446.
Walsh J.H., Pounder R.E., Damman H.G., Humphries T.J. (1998) Rabeprazole 20 mg is optimal therapy for acute acid related diseases: Pharmacodynamic perspective. Digestion , abstract; 59(S3):234.
Hongo M., Kimpara T., Moriyama S. (1998) Effect of rabeprazole (E3810), a novel proton pump inhibitor, on intragastric pH in healthy volunteers. Tohoku J Exp Med 186:43-50.
Robinson M., Maton P.N., Rodriguez S. (1997) Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 11:973-980.
Gardner J.D., Sloan S., Barth J.A. (1999) Onset, duration, and magnitude of gastric antisecretory effects of rabeprazole and omeprazole. Am J Gastroenterol , abstract; 94.
Galmiche J.P., Zerlib F., Ducrotte P. (2001) Decreasing oesophageal acid exposure in patients with GERD: A comparison of rabeprazole and omeprazole. Aliment Pharmacol Ther 15:1343-1350.
Sloan S., Camacho F., Padomo C. (2000) Rabeprazole is comparable in efficacy to omeprazole in erosive GORD and provides more rapid heartburn relief. Gut , abstract; 47(S3).
Holtman G., Bytzer P., Blum A. (2002) Clinical efficacy of a standard dose rabeprazole and a high dose of omeprazole for the relief of GORD symptoms. Aliment Pharmacol Ther, submitted; .
Birbara C., Breiter J., Perdomo C., Hahne W. (2000) Rabeprazole for the prevention of recurrent erosive or ulcerative gastroesophageal reflux disease. Eur J Gastroenterol 12:889-897.
Caos A., Moskovitz M., Perdomo C. (2000) Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Am J Gastroenterol 95:3081-3088.
Thjodleifsson B., Beker J.A., Dekkers C. (2000) Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastro-oesophageal reflux disease: A double-blind, multicentre European trial. Dig Dis Sci 45:845-853.
Breiter J.R., Riff D., Humphries T.J. (2000) Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: Results of a double-blind, randomised North American study. Am J Gastroenterol 95:936-942.
Dekkers C.P.M., Beker J.A., Thjodleifsson B. (1998) Comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of active gastric ulcer- a European multicentre study. Aliment Pharmacol Ther 12:789-795.
Dekkers C.P.M., Beker J.A., Thjodleifsson B. (1999) Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: A European multicentre study. Aliment Pharmacol Ther 13:179-186.
Yasutake K., Nishizaki A., Kyou K. (1999) Study on the time necessary for the relief of subjective symptoms (pain) in patients with ulcerative lesions in the upper GI tract treated with acid secretion inhibitors (H2 receptor antagonists and proton pump inhibitors). J New Remedies Clin 48:34-42.
Fujiyama K., Fujioka T., Kodama R., Nasu M. (1994) Effect of E3810, a novel proton pump inhibitor, against Helicobacter pylori. Am J Gastroenterol , abstract; 89:1371.
Stack W.A., Knifton A., Thirlwell D. (1998) Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenterol 93:1909-1913.
Miwa H., Ohkura R., Murai T. (1999) Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection- comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 13:741-746.
Hawkey C.J. (2001) Rabeprazole versus omeprazole in a 7 day, triple-therapy H. pylori eradicator regimens for peptic ulcus. Gut , abstract; 48(S1).
Monographie Pariet® (rabéprazole), Janssen-Cilag; 2001.